Finnegan Score, NAS, Chart, Sheet, Newborn Baby, vs ESC, Interpretation & System

Finnegan Score:

• What is Finnegan Score?
• NAS (Neonatal Abstinence Syndrome)
• Chart
• Sheet
• Newborn Baby
• vs ESC
• Interpretation & System

What is Finnegan Score?

The Finnegan Score, also known as the Finnegan Neonatal Abstinence Scoring System (FNASS), is a standardized clinical tool used to assess withdrawal symptoms in newborn babies exposed to drugs, especially opioids, during pregnancy. It is one of the most widely used scoring systems in neonatal intensive care units (NICUs) worldwide. The purpose of this scoring system is to quantify the severity of withdrawal symptoms so that healthcare providers can determine whether treatment is needed and monitor the effectiveness of therapy over time.

The Finnegan Score evaluates more than 20 clinical signs, including neurological, gastrointestinal, and autonomic symptoms such as tremors, irritability, high-pitched crying, poor feeding, vomiting, and sweating. Each symptom is assigned a numerical value based on its severity, and the total score is calculated at regular intervals. This structured approach helps clinicians make consistent and evidence-based decisions, ensuring that newborns receive timely and appropriate care for withdrawal symptoms.

NAS (Neonatal Abstinence Syndrome)

Neonatal Abstinence Syndrome (NAS) refers to a group of symptoms experienced by newborns who have been exposed to addictive substances in utero, most commonly opioids such as heroin, methadone, or prescription pain medications. After birth, the sudden discontinuation of these substances leads to withdrawal symptoms as the baby’s body adapts to the absence of the drug. NAS can vary in severity, ranging from mild irritability to severe complications requiring intensive medical care.

The Finnegan Score plays a central role in diagnosing and managing NAS. By systematically assessing symptoms every 2 to 4 hours, healthcare providers can track the progression of withdrawal and determine when pharmacologic treatment is necessary. Non-pharmacologic care, such as swaddling, reduced stimulation, and frequent feeding, is often the first line of management. However, higher Finnegan scores may indicate the need for medications like morphine or methadone to control symptoms effectively.

Chart

The Finnegan Score chart is a detailed table that lists all the clinical signs associated with neonatal withdrawal, along with corresponding scores. These signs are grouped into categories such as central nervous system disturbances (e.g., tremors, seizures), metabolic and autonomic disturbances (e.g., sweating, fever), and gastrointestinal disturbances (e.g., vomiting, diarrhea). Each sign is scored based on its intensity, allowing clinicians to calculate a total score for each assessment.

The chart is designed to standardize evaluation and reduce subjectivity among different healthcare providers. By using the same chart across shifts and caregivers, consistency in scoring is maintained, which is essential for accurate monitoring. The chart is typically displayed in NICUs or included in patient records so that it can be referenced easily during each assessment interval.

Sheet

A Finnegan Score sheet is a documentation tool used to record the scores assigned during each assessment. It includes spaces for time intervals, individual symptom scores, and the total score. The sheet allows healthcare providers to track trends over time, helping them evaluate whether the newborn’s condition is improving, worsening, or remaining stable.

The scoring sheet is an important part of clinical documentation and communication among the healthcare team. It ensures that all observations are recorded systematically and can be reviewed during rounds or treatment planning. Proper use of the sheet helps prevent errors and ensures that treatment decisions are based on accurate and up-to-date information.

Newborn Baby

In a newborn baby, NAS symptoms usually appear within the first 24 to 72 hours after birth, although the timing may vary depending on the substance involved. Babies may exhibit excessive crying, jitteriness, feeding difficulties, and sleep disturbances. These symptoms can be distressing for both the infant and caregivers, requiring careful monitoring and supportive care.

The Finnegan Score is specifically designed for newborns and takes into account their unique physiological responses. By closely monitoring these infants, healthcare providers can intervene early and reduce the risk of complications. Family involvement and supportive care, such as skin-to-skin contact and a calm environment, are also important in managing NAS in newborns.

vs ESC

The Finnegan Score is often compared with the newer Eat, Sleep, Console (ESC) approach for managing NAS. While the Finnegan system focuses on scoring individual symptoms, ESC evaluates the baby’s ability to eat effectively, sleep adequately, and be consoled within a reasonable time. ESC is considered a more functional and family-centered approach.

Studies have shown that ESC may reduce the need for pharmacologic treatment and shorten hospital stays compared to the Finnegan system. However, the Finnegan Score remains widely used due to its detailed and standardized assessment. Many healthcare facilities are now integrating both approaches to provide comprehensive care for infants with NAS.

Interpretation & System

Interpreting the Finnegan Score involves evaluating the total score and identifying trends over time. Generally, a score of 8 or higher on two consecutive assessments suggests significant withdrawal and may indicate the need for medication. A single score above 12 is also considered a strong indicator for initiating treatment. Lower scores typically suggest mild symptoms that can be managed with supportive care alone.

The Finnegan system emphasizes regular monitoring, consistency in scoring, and clinical judgment. It is not used in isolation but combined with the baby’s overall clinical condition and response to treatment. By following this structured system, healthcare providers can ensure that newborns with NAS receive timely, effective, and individualized care.